RCD – Rousaud Costas Duran has advised AlbaJuna Therapeutics, a spin-off from the IrsiCaixa AIDS Research Institute, on the investment of €3.75M by the pharmaceutical company Grifols, which will support the development of therapeutic antibodies to fight HIV. The amount invested is expected to increase as each molecule development stage is completed.
RCD reinforces its Administrative and Urban Planning Department with the incorporation of Enric Acero, formerly the Municipal Secretary of Parets del Vallès Town Council and Secretary of its Industrial Board.
Rousaud Costas Duran has been one of the most active firms in the transactional market throughout 2015, according to the most relevant rankings of the sector such as TTR (Transactional Track Record) or Bloomberg.
Rousaud Costas Duran has advised Rastar Group, a leading manufacturer and distributor of electronic toys in China, on the acquisition of 54% of the capital share of the Spanish soccer team RCD Espanyol, SAD.
RCD – Rousaud Costas Duran has advised the biotech company Aelix Therapeutics on an €11.5M investment round; the money will be used to develop an effective vaccine against the HIV virus. Ysios Capital, a Spanish investment fund, led the round. The fundraising was also supported by Caixa Capital Risc and the American fund Johnson & Johnson Innovation.
